Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies

ABSTRACT Bocidelpar is a peroxisome proliferator‐activated receptor δ modulator designed to address mitochondrial impairment. Two open‐label, single‐dose phase 1 studies (NCT05117294/NCT04942964) investigated the effect of severe renal or mild/moderate hepatic impairment on bocidelpar pharmacokineti...

Full description

Bibliographic Details

Published in:	Clinical and Translational Science
Main Authors:	Megumi Iwai, Nakyo Heo, Kentaro Hashimoto, Sayuri Guro, Selina Moy, Anna Spence, Tomasz Wojtkowski, Lauren Benner, Melanie Helmick, Tong Zhu, Brian C. Ferslew
Format:	Article
Language:	English
Published:	Wiley 2025-08-01
Subjects:	hepatic pharmacokinetics phase I renal
Online Access:	https://doi.org/10.1111/cts.70310